A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

LESSONS LEARNED. The combination of pexidartinib and binimetinib was safe and tolerable and demonstrated encouraging signs of efficacy in two patients with advanced gastrointestinal stromal tumor (GIST) refractory to tyrosine kinase inhibitors (TKIs). Molecular profiling of GISTs at diagnosis and up...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Rosenbaum, Evan, Kelly, Ciara, D'Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal, Keohan, Mary L., Movva, Sujana, Condy, Mercedes, Adamson, Travis, Mcfadyen, Chloe R., Antonescu, Christina R., Hwang, Sinchun, Singer, Sam, Qin, Li‐Xuan, Tap, William D., Chi, Ping
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Inc. 2019
Pynciau:
Clinical Trial Results
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795162/
https://ncbi.nlm.nih.gov/pubmed/31213500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0418
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg